AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17265078 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine alone
Number of subjects: 20
Study 14692927 — intervention group
Group type: COMPARATOR
Intervention: Post punch‐grafting PUVA (group I)
Number of subjects: 42
Study 14692927 — intervention group
Group type: EXPERIMENTAL
Intervention: Post punch‐grafting topical application of fluocinolone acetonide 0.1% (group II)
Number of subjects: 42
Study 11009194 — intervention group
Group type: EXPERIMENTAL
Intervention: Cued physical therapy
Number of subjects: 20
Study 11009194 — intervention group
Group type: COMPARATOR
Intervention: Non-cued physical therapy
Number of subjects: 20
Study 9180192 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 microg and 20 microg doses at 0 and 6 months
Number of subjects: 199
Study 9180192 — intervention group
Group type: COMPARATOR
Intervention: Three 10-microg doses at 0, 1, and 6 months
Number of subjects: 199
Study 8238144 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg of aspirin daily
Number of subjects: 59
Study 8238144 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 8238144 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin with fourfold thromboxane B2 reduction
Number of subjects: 59
Study 8238144 — intervention group
Group type: COMPARATOR
Intervention: Remaining patients without fourfold thromboxane B2 reduction
Number of subjects: 59
Study 4089575 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid-formula diet (LFD) for 2 weeks followed by protein-sparing modified fast (PSMF) for 4 weeks
Number of subjects: 41
Study 4089575 — intervention group
Group type: COMPARATOR
Intervention: Protein-sparing modified fast (PSMF) for 6 weeks
Number of subjects: 41
Study 30063840 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring intervention for asthma management
Number of subjects: 100
Study 30063840 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard management)
Number of subjects: 100
Study 30135834 — intervention group
Group type: EXPERIMENTAL
Intervention: iCBT
Number of subjects: 270
Study 30135834 — intervention group
Group type: EXPERIMENTAL
Intervention: bCBT
Number of subjects: 270
Study 30135834 — intervention group
Group type: EXPERIMENTAL
Intervention: bMED
Number of subjects: 270
Study 30135834 — intervention group
Group type: COMPARATOR
Intervention: WLC
Number of subjects: 270
Study 27798902 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab (8 mg/kg) and Paclitaxel (90 mg/m2) every three weeks
Number of subjects: 3
Study 27798902 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic analysis
Number of subjects: 3
Study 25427305 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue
Number of subjects: 30
Study 25427305 — intervention group
Group type: COMPARATOR
Intervention: Cyanoacrylate glue
Number of subjects: 30
Study 22104603 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathmobile plus FACI
Number of subjects: 322
Study 22104603 — intervention group
Group type: EXPERIMENTAL
Intervention: FACI only
Number of subjects: 322
Study 22104603 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathmobile only
Number of subjects: 322
Study 22104603 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 322
Study 20225477 — intervention group
Group type: EXPERIMENTAL
Intervention: Gel-to-foam dentifrice (Aquafresh Iso-active)
Number of subjects: 36
Study 20225477 — intervention group
Group type: COMPARATOR
Intervention: Aquafresh Fresh & Minty (Control)
Number of subjects: 36
Study 20225477 — intervention group
Group type: COMPARATOR
Intervention: Aquafresh Extreme Clean (Control)
Number of subjects: 36
Study 17381486 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream (2.5 g)
Number of subjects: 99
Study 17381486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 15367249 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg of bupropion SR daily and PTC (n=382)
Number of subjects: 1524
Study 15367249 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg of bupropion SR daily and PTC (n=383)
Number of subjects: 1524
Study 15367249 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg of bupropion SR daily and TM (n=381)
Number of subjects: 1524
Study 15367249 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg of bupropion SR daily and TM (n=378)
Number of subjects: 1524
Study 11318882 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine hydrochloride tablets (median daily dose of 14 mg, mean 13.5 mg, SD 4.3, range 4 to 20 mg, divided over three doses per day)
Number of subjects: 39
Study 11318882 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine hydrochloride tablets
Number of subjects: 39
Study 9840539 — intervention group
Group type: EXPERIMENTAL
Intervention: High fiber supplement
Number of subjects: 119
Study 9840539 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained volunteers (VARs)
Number of subjects: 119
Study 8126535 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated breath-by-breath method
Number of subjects: 10
Study 8126535 — intervention group
Group type: COMPARATOR
Intervention: Graphic manual recording
Number of subjects: 10
Study 2777852 — intervention group
Group type: EXPERIMENTAL
Intervention: Ender nailing
Number of subjects: 60
Study 2777852 — intervention group
Group type: COMPARATOR
Intervention: External fixation
Number of subjects: 60
Study 1152797 — intervention group
Group type: EXPERIMENTAL
Intervention: VIDaP-scheme
Number of subjects: 67
Study 1152797 — intervention group
Group type: EXPERIMENTAL
Intervention: cytosinarabinosid
Number of subjects: 67
Study 1152797 — intervention group
Group type: COMPARATOR
Intervention: methotrexat-purinethol-prednisone
Number of subjects: 67
Study 1152797 — intervention group
Group type: EXPERIMENTAL
Intervention: patients below 20 years old
Number of subjects: 67
Study 1152797 — intervention group
Group type: EXPERIMENTAL
Intervention: patients over 60 years old
Number of subjects: 67
Study 31133494 — intervention group
Group type: EXPERIMENTAL
Intervention: Three consecutive monthly treatments with selamectin (5.25–6.60 mg/kg) and sarolaner (0.88–1.10 mg/kg) on Days 0, 30, and 60
Number of subjects: 24
Study 31133494 — intervention group
Group type: EXPERIMENTAL
Intervention: Single treatment with fluralaner (34.71–43.08 mg/kg) on Day 0 and placebo on Days 30 and 60
Number of subjects: 24
Study 31133494 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle control for Revolution® Plus) on Days 0, 30, and 60
Number of subjects: 24
Study 28403598 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy with Prulifloxacine, 400 mg/day for 5 days
Number of subjects: 80
Study 28403598 — intervention group
Group type: COMPARATOR
Intervention: Association of D-mannose and NAC therapy, two vials/day for 7 days
Number of subjects: 80
Study 26083704 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - 12-week guided skiing program
Number of subjects: 31
Study 26083704 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 31
Study 24267043 — intervention group
Group type: EXPERIMENTAL
Intervention: Cayenne pepper (500 mg, 1.25 mg capsaicin)
Number of subjects: 11
Study 24267043 — intervention group
Group type: EXPERIMENTAL
Intervention: Evodiamine (500 mg)
Number of subjects: 11
Study 24267043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 22384541 — intervention group
Group type: EXPERIMENTAL
Intervention: Wenshen Yangxue Granule (WSYXG)
Number of subjects: 90
Study 22384541 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Wenshen Yangxue Granule (WSYXG) and Clomifene Citrate (CC)
Number of subjects: 90
Study 22384541 — intervention group
Group type: COMPARATOR
Intervention: Clomifene Citrate (CC)
Number of subjects: 90
Study 20088418 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint group (12 cases)
Number of subjects: 21
Study 20088418 — intervention group
Group type: COMPARATOR
Intervention: Non-acupoint group (9 cases)
Number of subjects: 21
Study 16427437 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (120 to 150 mg a day continuous infusion)
Number of subjects: 72
Study 16427437 — intervention group
Group type: COMPARATOR
Intervention: Control group (prophylactic hypervolemic and hemodilution therapy plus nimodipine)
Number of subjects: 72
Study 15203946 — intervention group
Group type: EXPERIMENTAL
Intervention: CD ROM home-study course
Number of subjects: 1300
Study 15203946 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet/workbook home-study course
Number of subjects: 1300
Study 15203946 — intervention group
Group type: COMPARATOR
Intervention: Classroom instruction
Number of subjects: 1300
Study 15203946 — intervention group
Group type: COMPARATOR
Intervention: Workbook home-study course
Number of subjects: 1300
Study 11403751 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic therapy
Number of subjects: 21
Study 8989001 — intervention group
Group type: COMPARATOR
Intervention: 0 micrograms fentanyl
Number of subjects: 64
Study 8989001 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms fentanyl
Number of subjects: 64
Study 8989001 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 micrograms fentanyl
Number of subjects: 64
Study 7901637 — intervention group
Group type: EXPERIMENTAL
Intervention: Homologous blood transfusion
Number of subjects: 120
Study 7901637 — intervention group
Group type: COMPARATOR
Intervention: Autologous blood transfusion
Number of subjects: 120
Study 2961362 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol (0-2%)
Number of subjects: 10
Study 2961362 — intervention group
Group type: EXPERIMENTAL
Intervention: L-714,465 (0-4%)
Number of subjects: 10
Study 2961362 — intervention group
Group type: COMPARATOR
Intervention: Placebo (methyl cellulose)
Number of subjects: 10
Study 2961362 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (72 micrograms)
Number of subjects: 10
Study 31889367 — intervention group
Group type: EXPERIMENTAL
Intervention: Orve + wrap® blanket
Number of subjects: 129
Study 31889367 — intervention group
Group type: COMPARATOR
Intervention: Forced Air Warming
Number of subjects: 129
Study 28156253 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular treatment in patients with severe carotid stenosis (≥ 70%)
Number of subjects: 278
Study 28156253 — intervention group
Group type: COMPARATOR
Intervention: Endovascular treatment in patients with less than 70% stenosis (< 70%)
Number of subjects: 278
Study 26968165 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 IU/day vitamin D3
Number of subjects: 132
Study 26968165 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 IU/day vitamin D3
Number of subjects: 132
Study 26968165 — intervention group
Group type: EXPERIMENTAL
Intervention: 1200 IU/day vitamin D3
Number of subjects: 132
Study 26968165 — intervention group
Group type: EXPERIMENTAL
Intervention: 1600 IU/day vitamin D3
Number of subjects: 132
Study 25097273 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 60
Study 25097273 — intervention group
Group type: COMPARATOR
Intervention: Chlordiazepoxide
Number of subjects: 60
Study 22906959 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent vaccine (Gardasil; Merck)
Number of subjects: 356
Study 22906959 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent vaccine (Cervarix; GlaxoSmithKline)
Number of subjects: 356
Study 20515600 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A plus upper limb therapy programme
Number of subjects: 333
Study 20515600 — intervention group
Group type: COMPARATOR
Intervention: Upper limb therapy programme alone
Number of subjects: 333
Study 18540910 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (100 mg/d) + Cognitive‐Behavioral Therapy (CBT) + medication clinic
Number of subjects: 240
Study 18540910 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (100 mg/d) + BRENDA + medication clinic
Number of subjects: 240
Study 18540910 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (100 mg/d) + medication clinic with limited therapeutic content
Number of subjects: 240
Study 18540910 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Cognitive‐Behavioral Therapy (CBT) + medication clinic
Number of subjects: 240
Study 18540910 — intervention group
Group type: COMPARATOR
Intervention: Placebo + BRENDA + medication clinic
Number of subjects: 240
Study 18540910 — intervention group
Group type: COMPARATOR
Intervention: Placebo + medication clinic with limited therapeutic content
Number of subjects: 240
Study 15982594 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IP) - two periods of 2-min ischemia followed by 3-min reperfusion by aortic cross-clamped.
Number of subjects: 86
Study 15982594 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ischemic preconditioning).
Number of subjects: 86
Study 12925457 — intervention group
Group type: EXPERIMENTAL
Intervention: HEPACOAT stent with aspirin alone
Number of subjects: 200
Study 11078836 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotic membrane transplant
Number of subjects: 0
Study 11078836 — intervention group
Group type: COMPARATOR
Intervention: Conjunctival advancement
Number of subjects: 0
Study 8791051 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral Incision of the Prostate (TUIP)
Number of subjects: 60
Study 8791051 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral Resection of the Prostate (TURP)
Number of subjects: 60
Study 8791051 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral Balloon Dilatation of the Prostate (TUBDP)
Number of subjects: 60
Study 1519989 — intervention group
Group type: EXPERIMENTAL
Intervention: High UAC (n = 36)
Number of subjects: 69
Study 1519989 — intervention group
Group type: COMPARATOR
Intervention: Low UAC (n = 33)
Number of subjects: 69
Study 6337611 — intervention group
Group type: EXPERIMENTAL
Intervention: mianserin (30 to 90 mg)
Number of subjects: 58
Study 6337611 — intervention group
Group type: EXPERIMENTAL
Intervention: maprotiline (75 to 225 mg)
Number of subjects: 58
Study 6337611 — intervention group
Group type: COMPARATOR
Intervention: placebo (1 to 3 capsules)
Number of subjects: 58
Study 6337611 — intervention group
Group type: EXPERIMENTAL
Intervention: mianserin
Number of subjects: 58
Study 6337611 — intervention group
Group type: EXPERIMENTAL
Intervention: maprotiline
Number of subjects: 58
Study 6337611 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 58
Study 6337611 — intervention group
Group type: EXPERIMENTAL
Intervention: mianserin and maprotiline
Number of subjects: 58
Study 31295265 — intervention group
Group type: EXPERIMENTAL
Intervention: High identity entrepreneurship condition
Number of subjects: 72
Study 31295265 — intervention group
Group type: COMPARATOR
Intervention: Low identity entrepreneurship condition
Number of subjects: 72
Study 28362562 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg daily
Number of subjects: 946
Study 28362562 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 800 mg daily
Number of subjects: 946
Study 25649338 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous electric neurostimulation (PENS) of dermatome T7 (12 sessions of 30 minutes weekly) associated with a 1,200 Kcal/day diet
Number of subjects: 60
Study 25649338 — intervention group
Group type: COMPARATOR
Intervention: 1,200 Kcal/day diet
Number of subjects: 60
Study 23179965 — intervention group
Group type: EXPERIMENTAL
Intervention: THC (0.015 to 0.05 mg/kg)
Number of subjects: 44
Study 21834670 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% topical povidone-iodine
Number of subjects: 164
Study 21834670 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% ciprofloxacin
Number of subjects: 164
Study 21834670 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% ofloxacin
Number of subjects: 164
Study 19366970 — intervention group
Group type: EXPERIMENTAL
Intervention: Taspoglutide 5 mg once weekly
Number of subjects: 306
Study 19366970 — intervention group
Group type: EXPERIMENTAL
Intervention: Taspoglutide 10 mg once weekly
Number of subjects: 306
Study 19366970 — intervention group
Group type: EXPERIMENTAL
Intervention: Taspoglutide 20 mg once weekly
Number of subjects: 306
Study 19366970 — intervention group
Group type: EXPERIMENTAL
Intervention: Taspoglutide 10 mg once every 2 weeks
Number of subjects: 306
Study 19366970 — intervention group
Group type: EXPERIMENTAL
Intervention: Taspoglutide 20 mg once every 2 weeks
Number of subjects: 306
Study 19366970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study 16736432 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer hydrochloride
Number of subjects: 16
Study 16736432 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate
Number of subjects: 16
Study 11823257 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 2214
Study 11823257 — intervention group
Group type: COMPARATOR
Intervention: Conventional antipsychotics
Number of subjects: 2214
Study 10082852 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased protein levels of BDNF (Brain-Derived Neurotrophic Factor)
Number of subjects: 0
Study 10082852 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of BDNF with neuropeptide Y
Number of subjects: 0
Study 8963158 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocabastine eye drops (0.5 mg/ml, single dose)
Number of subjects: 32
Study 8963158 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocabastine eye drops (0.5 mg/ml, one drop in each eye twice daily for two weeks)
Number of subjects: 32
Study 8963158 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 32
Study 2170144 — intervention group
Group type: EXPERIMENTAL
Intervention: Free sucrose (morning snack)
Number of subjects: 18
Study 2170144 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose plus fibre (morning snack)
Number of subjects: 18
Study 2170144 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose plus fibre (morning snack)
Number of subjects: 18
Study 2170144 — intervention group
Group type: EXPERIMENTAL
Intervention: Free sucrose (afternoon snack)
Number of subjects: 18
Study 2170144 — intervention group
Group type: COMPARATOR
Intervention: No snack (morning and afternoon)
Number of subjects: 18
Study 7429441 — intervention group
Group type: EXPERIMENTAL
Intervention: Winning a doubles tennis match with decisive victory
Number of subjects: 3
Study 7429441 — intervention group
Group type: EXPERIMENTAL
Intervention: Winning a doubles tennis match (close match)
Number of subjects: 3
Study 7429441 — intervention group
Group type: EXPERIMENTAL
Intervention: Winning $100 in a lottery (effortless win)
Number of subjects: 3
Study 7429441 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiving M.D. degree at graduation
Number of subjects: 3
Study 6345281 — intervention group
Group type: EXPERIMENTAL
Intervention: ursodeoxycholic acid 12 mg/kg
Number of subjects: 28
Study 6345281 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 28
Study 30970218 — intervention group
Group type: EXPERIMENTAL
Intervention: ω‐3 supplementation (3 g eicosapentaenoic acid, 2 g docosahexaenoic acid)
Number of subjects: 20
Study 30970218 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study 29884161 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐intervention group (n = 62) received a 6‐month web‐delivered intensive dietary intervention
Number of subjects: 128
Study 29884161 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐intervention group (n = 62)
Number of subjects: 128
Study 29884161 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 66)
Number of subjects: 128
Study 26589401 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised rehabilitation therapy (weekly sessions with facial exercises and massages, daily facial exercises at home)
Number of subjects: 79
Study 26589401 — intervention group
Group type: COMPARATOR
Intervention: Daily homework manual for ordinary postoperative facial mimic exercises (autonomously at home)
Number of subjects: 79
Study 24656762 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous case management including participation in a psychoeducation program
Number of subjects: 0
Study 24656762 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 0
Study 23019939 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled sedation with transcutaneous electrical stimulation of auricular Shenmen (TF4)
Number of subjects: 180
Study 23019939 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled sedation with transcutaneous electrical stimulation of auricular eye point
Number of subjects: 180
Study 23019939 — intervention group
Group type: COMPARATOR
Intervention: Control group (pressurization without electric stimulation)
Number of subjects: 180
Study 20404762 — intervention group
Group type: EXPERIMENTAL
Intervention: BAR plus water (solid CHO)
Number of subjects: 8
Study 20404762 — intervention group
Group type: EXPERIMENTAL
Intervention: DRINK (liquid CHO)
Number of subjects: 8
Study 20404762 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 8
Study 19091127 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg/day of astaxanthin
Number of subjects: 66
Study 19091127 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 15716221 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP educational video
Number of subjects: 0
Study 15716221 — intervention group
Group type: COMPARATOR
Intervention: Control group (no video)
Number of subjects: 0
Study 12094249 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (DOX) 30 mg/m² administered from days 1 to 3 and days 8 to 10, along with vincristine, prednisolone, cyclophosphamide, and L‐asparaginase, followed by three courses of consolidation and four courses of intensification
Number of subjects: 285
Study 12094249 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 285
Study 12094249 — intervention group
Group type: EXPERIMENTAL
Intervention: Allo-BMT
Number of subjects: 285
Study 10616629 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic schizophrenia
Number of subjects: 27
Study 10616629 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic schizophrenia (female patients)
Number of subjects: 27
Study 10616629 — intervention group
Group type: EXPERIMENTAL
Intervention: First-episode schizophrenia
Number of subjects: 27
Study 10616629 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 27
Study 8532923 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal intermittent positive pressure ventilation (NIPPV)
Number of subjects: 20